# A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor

> **NCT07105111** · PHASE4 · RECRUITING · sponsor: **Neurocrine Biosciences** · enrollment: 50 (estimated)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Bipolar Disorder
- Major Depressive Disorder
- Tardive Dyskinesia

## Interventions

- **DRUG:** Valbenazine

## Key facts

- **NCT ID:** NCT07105111
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-29
- **Primary completion:** 2027-01
- **Final completion:** 2027-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07105111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07105111, "A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT07105111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*